Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Qualitative susceptibility tests versus quantitative MIC tests

W A Craig1

  • 1Department of Medicine, William S. Middleton Memorial Veterans Hospital, Madison, WI 53705.

Diagnostic Microbiology and Infectious Disease
|March 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

Antimicrobial agents and chemotherapy·2014
Same author

In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

Antimicrobial agents and chemotherapy·2013
Same author

In vivo pharmacodynamics of new lipopeptide MX-2401.

Antimicrobial agents and chemotherapy·2010
Same author

In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.

Antimicrobial agents and chemotherapy·2008
Same author

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.

Antimicrobial agents and chemotherapy·2006
Same author

Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.

Antimicrobial agents and chemotherapy·2005
Same journal

Multiplex mismatch amplification mutation polymerase chain reaction assay for the rapid detection of antimicrobial-resistant determinants in Cutibacterium acnes.

Diagnostic microbiology and infectious disease·2026
Same journal

Tularemia-associated septic shock with pneumonia, lung abscesses, and pleural effusion leading to multiorgan failure: Is Francisella tularensis still a deadly pathogen in the antibiotic era? A case report.

Diagnostic microbiology and infectious disease·2026
Same journal

Impact of Xpert® MRSA/SA blood culture PCR test on antimicrobial utilization at a large teaching hospital.

Diagnostic microbiology and infectious disease·2026
Same journal

Disseminated Mucormycosis and monoclonal gammopathy in a young sarcoidosis patient following COVID-19: A rare case report.

Diagnostic microbiology and infectious disease·2026
Same journal

Human septic arthritis caused by Spiroplasma turonicum.

Diagnostic microbiology and infectious disease·2026
Same journal

Enhanced stability of RPA-CRISPR-Cas12a system for respiratory pathogen detection using Trehalose-Carboxymethyl Chitosan Lyoprotectant.

Diagnostic microbiology and infectious disease·2026
See all related articles

Quantitative minimum inhibitory concentration (MIC) testing shows potential for personalizing antimicrobial therapy and optimizing drug dosage. Further research is needed to fully realize its clinical efficacy and cost-saving benefits.

Area of Science:

  • Microbiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Qualitative antimicrobial susceptibility categories offer limited correlation with treatment success.
  • Quantitative minimum inhibitory concentration (MIC) testing reveals higher MICs in treatment failures within the susceptible range.

Purpose of the Study:

  • To explore the potential of quantitative MIC tests for individualizing antimicrobial therapy.
  • To assess the correlation between pharmacokinetic parameters, MICs, and therapeutic outcomes.

Main Methods:

  • Analysis of studies correlating MIC values with treatment outcomes.
  • Review of dose-response data from animal infection models.
  • Examination of pharmacokinetic/pharmacodynamic (PK/PD) parameter ratios (e.g., peak level to MIC ratio).

Related Experiment Videos

Main Results:

  • Quantitative MIC tests show better correlation with therapeutic outcomes than qualitative categories.
  • Higher MICs are linked to treatment failures even in susceptible organisms.
  • Increased pharmacokinetic parameter to MIC ratios correlate with enhanced treatment response.
  • Animal models demonstrate a strong link between drug dose, efficacy, and MIC.

Conclusions:

  • Quantitative MIC testing offers greater potential for optimizing drug dosage and frequency compared to qualitative methods.
  • MICs can guide dose reduction for highly susceptible organisms, potentially lowering costs.
  • More research is required to establish consistent clinical efficacy and define the full utility of quantitative MIC testing.